Nektar Therapeutics - Asset Resilience Ratio
Nektar Therapeutics (NKTR) has an Asset Resilience Ratio of 58.92% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NKTR working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2025)
This chart shows how Nektar Therapeutics's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Nektar Therapeutics.
Liquid Assets Composition Over Time
This chart breaks down Nektar Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Nektar Therapeutics long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $645.23 Million | 58.92% |
| Total Liquid Assets | $645.23 Million | 58.92% |
Asset Resilience Insights
- Very High Liquidity: Nektar Therapeutics maintains exceptional liquid asset reserves at 58.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nektar Therapeutics Industry Peers by Asset Resilience Ratio
Compare Nektar Therapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Nektar Therapeutics (1997–2025)
The table below shows the annual Asset Resilience Ratio data for Nektar Therapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 82.25% | $230.64 Million | $280.41 Million | +12.82pp |
| 2024-12-31 | 69.43% | $210.97 Million | $303.85 Million | +2.02pp |
| 2023-12-31 | 67.42% | $268.34 Million | $398.03 Million | +8.77pp |
| 2022-12-31 | 58.65% | $416.75 Million | $710.60 Million | -4.79pp |
| 2021-12-31 | 63.44% | $708.74 Million | $1.12 Billion | +7.36pp |
| 2020-12-31 | 56.08% | $862.94 Million | $1.54 Billion | -6.05pp |
| 2019-12-31 | 62.13% | $1.23 Billion | $1.98 Billion | +9.09pp |
| 2018-12-31 | 53.04% | $1.14 Billion | $2.15 Billion | -4.22pp |
| 2017-12-31 | 57.26% | $291.37 Million | $508.87 Million | -0.66pp |
| 2016-12-31 | 57.92% | $329.46 Million | $568.87 Million | +7.45pp |
| 2015-12-31 | 50.47% | $253.37 Million | $502.06 Million | -0.59pp |
| 2014-12-31 | 51.05% | $225.46 Million | $441.62 Million | +5.50pp |
| 2013-12-31 | 45.56% | $197.96 Million | $434.53 Million | -5.02pp |
| 2012-12-31 | 50.57% | $251.76 Million | $497.79 Million | +13.34pp |
| 2011-12-31 | 37.24% | $225.86 Million | $606.55 Million | -19.97pp |
| 2010-12-31 | 57.21% | $298.18 Million | $521.23 Million | -3.02pp |
| 2009-12-31 | 60.23% | $346.61 Million | $575.52 Million | +20.37pp |
| 2008-12-31 | 39.86% | $223.41 Million | $560.54 Million | -16.14pp |
| 2007-12-31 | 56.00% | $406.06 Million | $725.10 Million | +4.60pp |
| 2006-12-31 | 51.40% | $394.88 Million | $768.18 Million | +26.37pp |
| 2005-12-31 | 25.03% | $214.93 Million | $858.55 Million | -17.16pp |
| 2004-12-31 | 42.20% | $314.33 Million | $744.92 Million | +6.22pp |
| 2003-12-31 | 35.98% | $221.92 Million | $616.79 Million | -6.73pp |
| 2002-12-31 | 42.71% | $259.09 Million | $606.64 Million | -4.28pp |
| 2001-12-31 | 46.99% | $313.54 Million | $667.24 Million | -8.42pp |
| 2000-12-31 | 55.41% | $348.83 Million | $629.54 Million | +9.22pp |
| 1999-12-31 | 46.19% | $104.75 Million | $226.81 Million | +3.10pp |
| 1998-12-31 | 43.08% | $57.95 Million | $134.50 Million | -28.08pp |
| 1997-12-31 | 71.16% | $85.22 Million | $119.76 Million | -- |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosi… Read more